CD274 and lung carcinoma: PD-L1 expressed on tumor cells has been listed by the FDA as a companion or complementary diagnosis for screening lung cancer patients treated with PD-1/PD-L1 treatment population as a concomitant or complementary diagnosis (18, 19).